Roche Pharmaceutical Development and Sales Overview

Exchange rate impact on sales growth Q3 2022: negative impact of JPY and EUR, positive impact of USD Development of average exchange rates versus prior year period CHF / USD 2.2% CHF / EUR -4.9% 5.9% -6.4% CHF/JPY -6.9% -10.6% Difference in CHF/CER -1.0% growth Sales growth 2022 vs. 2021 11.2% 10.2% CER growth CHF growth Q1 CER = Constant Exchange Rates (avg full year 2021) 5.2% -10.0% -16.2% 0.4% -2.1% 0.0% 0.4% Q2 22 -5.6% Q3 -7.7% Q4 Roche 182

View entire presentation